WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is best?
In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The…
Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg |…
Ireland business chamber welcomes Chinese investment despite US, EU pressures
Chinese investment is still being actively welcomed in Ireland, the head of a major business organisation said, even…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
ADHD Pills Beget Other Drugs, New Hormone Therapy Guidelines and Obesity Drug Price Cuts | WSJ Health for November 21
This is an edition of the WSJ Health newsletter, a weekly briefing on what’s new in health, medicine,…
Eli Lilly hits $1 trillion market value, first for health care company
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March…
What Comes After the FDA’s Drug Monopoly?
The FDA’s monopoly over drug and device approval—created by the 1938 Food, Drug, and Cosmetic Act and expanded…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…